A microneedle-based delivery system incorporating epigallocatechin gallate and L-ascorbic acid-loaded poly-γ-glutamic acid has been found to substantially ameliorate atopic dermatitis symptoms in mice, significantly decrease serum IgE and histamine levels, and downregulate Th2-type immune responses, ultimately enhancing atopic dermatitis outcomes (319). The gene discussed is IGHE; the disease is atopic eczema.